[email protected]

– USA, NY – Tyme Technologies, Inc. (OTCQB:TYMI), a specialty biotechnology company developing cancer therapeutics targeted at multiple tumor types, today announced the addition of Paul L. Sturman, a seasoned pharmaceutical executive with 30 years in the consumer health industry at Pfizer, Johnson & Johnson and Warner Lambert, to the company’s board of directors.

“As Tyme transforms from being an early-stage biotech company to a more fully integrated one, Paul’s expertise in managing complex organizations and building corporate culture will be invaluable,” said CEO Steve Hoffman. “Throughout his career in large pharma, Paul has a track record of consistently delivering growth in revenue, profitability and market share, underscored by a lifelong commitment to improving quality of healthcare and access through education. We look forward to his extensive experience and board leadership as we move forward.”

Mr. Sturman has worked in the healthcare industry in a variety of leadership positions. At Pfizer, Mr. Sturman ran the Global Consumer Healthcare division, one of the largest over-the-counter healthcare products companies in the world. He also previously served as President of J&J’s North American Consumer Health division as well as numerous leadership roles in marketing, brand, and sales management with Warner Lambert. He is a member of the Board of Trustees of the Foundation for Morristown Medical Center, one of “America’s Top 50 Hospitals,” which works to advance healthcare for patients by preserving and expanding programs and services in patient care, clinical research, medical and public health education, and preventive medicine.

About Tyme

Tyme Technologies is developing a novel first-in-class therapy, SM-88, that is designed to use cancer’s unusual metabolism to selectively break down the cellular defenses of tumors, leading to tumor cell death. Through clinical trials and expanded access programs, SM-88 has been used in over 84 individuals and shown a clinical response in thirteen cancer types. In its initial Phase I trial for end-stage, metastatic cancer patients, SM-88 treatment resulted in a median overall survival of 26 months, with 32% of patients alive at the end of the three year evaluation period without any drug-related serious adverse events. The Company is currently conducting a Phase Ib/II trial in prostate cancer in addition to ongoing collaborations with the Mayo Clinic, Mount Sinai, the Albert Einstein College of Medicine and other institutions.

For more information : http://www.tymeinc.com

- DisclaimerNews, data and statement included in this release are intended exclusively for information purposes. Product and brand names used in this release maybe trademarks or registered trade marks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.

Talent4Boards Team

here the original post =>

Comments are closed.